Efavirenz Metabolism and CNS Toxicity in Ugandan Children: Plasma Metabolite Profiles

99 Ugandan children aged 3–12 years were prospectively followed in 2015–2016, with plasma sampling at 2, 6, 12, and 24 weeks after initiating efavirenz-based antiretroviral therapy. Sandra Soeria-Atmadja authored this dataset quantifying efavirenz and its metabolites to explore associations with CYP2B6 genotypes and central nervous system adverse effects. The dataset was last updated on 2026-04-24.

Use Cases

• Modeling the relationship between CYP2B6 metabolizer phenotype and plasma metabolite ratios.
• Investigating associations between high efavirenz plasma concentrations and mild CNS symptoms.
• Studying autoinduction of efavirenz metabolism in extensive metabolizers over a 24-week period.
• Analyzing the distribution of conjugated versus unconjugated metabolite forms across different metabolizer phenotypes.

Strengths

• 99 pediatric patient records provide a specific cohort size.
• Longitudinal plasma sampling at four time points over 24 weeks.
• Includes genotyping data for CYP2B6 and CYP2A6 single nucleotide polymorphisms.
• Quantifies multiple efavirenz metabolites in both conjugated and unconjugated forms.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 27.5 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

Prospective clinical study with plasma sampling and genotyping.

Time Range

2015–2016

Freshness

Last updated 2026-04-24 05:40:34; freshness should be verified.

Geography

Uganda